Provided by Tiger Trade Technology Pte. Ltd.

Psyence Biomedical Ltd

5.82
-0.2500-4.12%
Pre-market: 5.860.0400+0.69%06:53 EDT
Volume:40.47K
Turnover:239.87K
Market Cap:22.20M
PE:-0.46
High:6.06
Open:6.03
Low:5.80
Close:6.07
52wk High:34.63
52wk Low:1.92
Shares:3.81M
Float Shares:1.09M
Volume Ratio:0.39
T/O Rate:3.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.5596
EPS(LYR):-12.5596
ROE:-58.62%
ROA:-31.33%
PB:1.31
PE(LYR):-0.46

Loading ...

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

Psyence Biomedical establishes Texas Ibogaine Research Corporation

TIPRANKS
·
Sep 14

Psyence BioMed Names John Thorne Project Lead at New Texas Ibogaine Unit TIRC

Reuters
·
Sep 14

NASDAQ Trade Halt Volatility Trading Pause at 12:58 Pm

Reuters
·
Aug 19

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

GlobeNewswire
·
Jul 13

Psyence Biomedical FY26 net loss widens to about USD 6.89 million

Reuters
·
Jun 23

A Look At Cigna Group’s Valuation As Analysts Clash Over PBM Transition And Spending Uncertainty

Simply Wall St.
·
Jun 05

Launch One Acquisition names Daniel Clifford Rogers audit committee chair after Stack resignation

Reuters
·
Jun 03

Psyence BioMed targets U.S. push for GMP ibogaine research, manufacturing

Reuters
·
May 16

Psyence Biomed Announces U.S. Strategic Engagement Initiative Focused on Gmp Ibogaine Research and Manufacturing

THOMSON REUTERS
·
May 15

Press Release: Omada Health Reports First Quarter 2026 Results

Dow Jones
·
May 08

Health Insurer Cigna Tops Estimates. Why the Stock Is Gaining. -- Barrons.com

Dow Jones
·
Apr 30

Cigna's Earnings Could Show It Has Cleared Away PBM Surprises -- Barrons.com

Dow Jones
·
Apr 30

Amarin Reports 2026 First Quarter Financial Results

GlobeNewswire
·
Apr 29

Psyence amends amalgamation agreement with GoldCoast Resource Corp

Reuters
·
Apr 24

Psyence BioMed doses first patient in Phase IIb NPX-5 adjustment disorder trial

Reuters
·
Apr 23

Psyence Biomed Initiates Patient Dosing in Phase Iib Trial Evaluating Npx-5 for Adjustment Disorder

THOMSON REUTERS
·
Apr 23

Press Release: Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Dow Jones
·
Apr 23

Top Premarket Decliners

MT Newswires Live
·
Apr 22

EXPLAINER-What to know about psychedelic therapies cited by Trump

Reuters
·
Apr 22